Celularity Inc. Class A Common Stock (CELU)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I begin with present earning power. Celularity is a 115-employee regenerative medicine company, and the filed numbers are not those of a healthy business. In fiscal year 2025, it reported revenue of $26.6M and a net loss of $91.7M, or diluted EPS of $-3.59. That was worse than fiscal year 2024, when revenue was $54.2M and net loss was $57.9M. The one bright spot is fiscal Q1 2026, the quarter ended 2026-03-31, when it reported revenue of $3.8M, net income of $874,000, and diluted EPS of $0.02. But that follows fiscal Q1 2025, the quarter ended 2025-03-31, with $11.4M revenue and a $19.8M net loss, so one quarter is not a trend. No durable moat is visible in the figures. The company depends on clinical and regulatory success, and its trailing free cash flow is -$13.3M. FairStock’s calculations show an FCF yield of -28.8% based on the 2026-10-13 close, ROCE of -32.32%, Piotroski F-Score of 2/9, and Altman Z-Score of -14.15. Those are distress signals, not defensive strengths. At the 2026-10-13 close of $1.42, the market cap is $46.1M, and FairStock’s P/E is -0.52. A negative multiple means there is no earnings-based valuation anchor. FairStock scores it 19/100 and classifies it as a TURNAROUND—loss in the latest year after earlier profits. Turnarounds can work, but they need cash, stable revenue, and credibility. With negative free cash flow and weak balance-sheet scores, dilution risk is real. Until Q1 2026’s profit repeats and cash burn stops, the numbers say speculative, not investment-grade.

In plain English: Celularity is a small healthcare company trying to develop cell therapies from placental tissue for conditions like diabetic foot ulcers and Crohn's disease. The business looks weak: it has been losing money, burning cash, and revenue fell in fiscal 2025. At $1.42 per share, the price looks speculative rather than cheap, because there is no steady profit or positive cash flow to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer